Table 1.
Demographic and clinical profiles of all subjects
| Characteristics and previous therapeutic strategies | n (%) |
|---|---|
| Gender | |
| Male | 25 (49.0) |
| Female | 26 (51.0) |
| Age | |
| < 54 years old | 24 (45.1) |
| ≥ 54 years old | 27 (54.9) |
| ECOG performance status | |
| 0–1 | 28 (54.9) |
| 2–3 | 23 (45.1) |
| Subtype | |
| Leiomyosarcoma | 11 (21.6) |
| Alveolar soft part sarcoma | 6 (11.8) |
| Rhabdomyosarcoma | 6 (11.8) |
| Clear cell sarcoma | 5 (9.8) |
| Myxofibrosarcoma | 5 (9.8) |
| Synovial sarcoma | 3 (5.9) |
| Malignant peripheral nerve sheath tumor | 3 (5.9) |
| Undifferentiated pleomorphic sarcoma | 3 (5.9) |
| Others | 9 (17.6) |
| Primary site | |
| Limb | 28 (54.9) |
| Trunk | 17 (33.3) |
| Others | 6 (11.8) |
| Metastasis present | |
| Lung | 33 (64.7) |
| Bone | 18 (35.3) |
| Liver | 6 (11.8) |
| Pancreas | 5 (9.8) |
| Brain | 3 (5.9) |
| Treatment lines | |
| 1 | 12 (23.5) |
| 2 | 24 (47.1) |
| ≥ 3 | 15 (29.4) |
| Prior chemotherapy | |
| Yes | 32 (62.7) |
| No | 19 (37.3) |
| Prior radiotherapy | |
| Yes | 9 (17.6) |
| No | 42 (82.4) |
| Prior antiangiogenic therapy | |
| Yes | 21 (41.2) |
| No | 30 (58.8) |
| Prior immunotherapy | |
| Yes | 4 (7.8) |
| No | 47 (92.2) |
Abbreviation: ECOG: Eastern Cooperative Oncology Group